A novel interstitial deletion on the long arm of chromosome 16 in a patient with chronic myelomonocytic leukemia.

Human Genetics Program, Hayward Genetics Center and Department of Pediatrics, Tulane University Health Science Center, 1430 Tulane Avenue, New Orleans, LA 70112
Cancer Genetics and Cytogenetics (Impact Factor: 1.93). 11/2005; 162(1):92-4. DOI: 10.1016/j.cancergencyto.2005.02.004
Source: PubMed
  • Cancer Genetics and Cytogenetics 10/1997; 98(2):157. DOI:10.1016/S0165-4608(97)90270-3 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A detailed deletion mapping of a series of human prostatic carcinomas, using restriction fragment length polymorphism (RFLP) analysis of all chromosomes, showed allelic losses on individual chromosomes at variable frequencies. Allelic losses occurred on chromosomal arms 8p, 10pq, 16q and 18q in more than 30% of the cases. Losses of genetic information from one or two of the chromosomes 8, 10, or 16 were always present in tumors showing allelic losses, indicating that genes on these chromosomes have a central role in prostatic cancer. A more extensive study of these chromosomes was thus carried out and showed the highest frequency of allelic deletions to occur on the short arm of chromosome 8 (65%) (where the minimally deleted region was between the PLAT locus and pter). The long arm of chromosome 16 had allelic deletions in 56% of informative cases, with three different break points (the most distal being between D16S4 and D16S7). Chromosome 10 exhibited a complex deletion pattern, showing allelic losses from both the short (p) and the long (q) arms, evidence of non-reciprocal translocations of the q arm, and monosomy in some cases. Our data indicate that tumor suppressor genes involved in the oncogenesis of prostatic carcinoma may be localized between 8pter and the PLAT locus and that additional/alternative tumor suppressor gamma are likely to be localized on chromosome 10 and on the long arm of chromosome 16. More aggressive tumors were accompanied by a high or frequency of allelic losses.
    Scandinavian journal of urology and nephrology. Supplementum 02/1991; 138:93-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The CTCF gene encodes for a transcriptional repressor of the c-myc oncogene and has previously been mapped to one of the smallest regions of overlapping interstitial deletions on chromosome 16q22.1 in invasive breast cancer. This chromosomal region is frequently deleted in both invasive lobular and ductal breast carcinomas. However, no target genes have been identified in invasive ductal breast cancer. We examined CTCF protein expression in 18 invasive ductal breast carcinomas using immunohistochemistry. Additionally, loss of heterozygosity (LOH) at chromosome 16q22.1 was determined and the complete cDNA sequence of CTCF was screened for mutations. Immunohistochemically, 17 tumours showed a moderate to strong nuclear staining for CTCF, one case was completely negative. Sequencing analysis revealed a tumour-specific truncating 14 bp insertion with silencing of the wild type allele in this case. In one further case we found a missense mutation that was shown not to be tumour-specific. Concordant with the antiproliferative effects of the CTCF protein in vivo, CTCF may be involved in tumour initiation or proliferation in individual cases of invasive ductal breast carcinoma.
    Breast Cancer Research and Treatment 09/2003; 80(3):347-52. DOI:10.1023/A:1024930404629 · 4.20 Impact Factor